Cardiosense develops a physiological waveform AI platform, novel digital tools, multi-sensor devices, and analysis algorithms to detect early signs of cardiovascular disease and inform personalized therapy. Its clinical application focuses on improving management of congestive heart failure (CHF). The company intends to use new funding to expand its team, accelerate product development, and support an expansive heart failure study. Cardiosense highlights the large CHF burden—more than 6 million people in the U.S. and projected healthcare costs exceeding $70 billion annually by 2030. Led by CEO Amit Gupta and based in Chicago, the company positions its technology to improve patient outcomes and therapy management.

Total raised

$15M

Funding rounds

1

Latest round

Series A

Latest activity

Dec 2022